Cabaletta Bio, Inc. (CABA) |
|
11.98 0.04 (0.34%)
|
06-06 16:00 |
|
Open: |
12 |
Pre. Close: |
11.94 |
|
High:
|
12.46 |
Low:
|
11.6501 |
|
Volume:
|
307,474 |
Market Cap:
|
476(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 4:26:42 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 15.69 One year: 18.33 |
| Support: |
Support1: 10.7 Support2: 9.02 |
| Resistance: |
Resistance1: 13.43 Resistance2: 15.69 |
| Pivot: |
11.07 |
| Moving Average: |
MA(5): 11.26 MA(20): 11.37
MA(100): 9.71 MA(250): 5.44 |
| MACD: |
MACD(12,26): 0.2 Signal(9): 0.2  |
| Stochastic oscillator: |
%K(14,3): 60.4 %D(3): 51.7 |
| RSI: |
RSI(14): 58.1 |
| 52-week: |
High: 13.43 Low: 0.58 |
| Average Vol(K): |
3-Month: 342 (K) 10-Days: 361 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CABA ] has closed below upper band by 30.0%. Bollinger Bands are 31.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
12.48 - 12.52 |
12.52 - 12.56 |
|
Low:
|
11.53 - 11.59 |
11.59 - 11.63 |
|
Close:
|
11.89 - 11.98 |
11.98 - 12.05 |
|
Company Description |
|
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania. |
Headline News |
Tue, 06 Jun 2023
Is Cabaletta Bio Inc (CABA) a Good Buy in the Healthcare Sector? - InvestorsObserver
Sun, 04 Jun 2023
Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation - Simply Wall St
Sat, 03 Jun 2023
Cabaletta Bio to Present at the Jefferies Healthcare Conference - MyChesCo
Fri, 02 Jun 2023
Director at Cabaletta Bio Acquires Company Stock Options Worth 22,000 Shares - Cabaletta Bio (NASDAQ:CABA - Benzinga
Mon, 22 May 2023
Prelude Therapeutics, Cabaletta Bio raise more than $200M combined in public stock sales - The Business Journals
Mon, 22 May 2023
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
40 (M) |
| Shares Float |
24 (M) |
|
% Held by Insiders
|
10.9 (%) |
|
% Held by Institutions
|
76.3 (%) |
|
Shares Short
|
3,980 (K) |
|
Shares Short P.Month
|
4,040 (K) |
Stock Financials |
|
EPS
|
-2.01 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.92 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-33.5 |
|
Return on Equity (ttm)
|
-56.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.44 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-46 (M) |
|
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
|
PE Ratio
|
-5.97 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
4.1 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-10.3 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
